VIA Pharmaceuticals, Inc.
VIAP
$0.00
$0.000.00%
OTC PK
| 12/31/2010 | 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.24M | 5.19M | 6.13M | 6.90M | 7.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.91M | 7.84M | 9.64M | 11.49M | 13.25M |
| Operating Income | -5.91M | -7.84M | -9.64M | -11.49M | -13.25M |
| Income Before Tax | -9.60M | -11.38M | -17.30M | -19.60M | -20.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.60 | -11.38 | -17.30 | -19.60 | -20.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.60M | -11.38M | -17.30M | -19.60M | -20.98M |
| EBIT | -5.91M | -7.84M | -9.64M | -11.49M | -13.25M |
| EBITDA | -5.84M | -7.74M | -9.52M | -11.35M | -13.12M |
| EPS Basic | -0.47 | -0.56 | -0.86 | -0.98 | -1.05 |
| Normalized Basic EPS | -0.29 | -0.35 | -0.53 | -0.61 | -0.66 |
| EPS Diluted | -0.47 | -0.56 | -0.86 | -0.98 | -1.05 |
| Normalized Diluted EPS | -0.29 | -0.35 | -0.53 | -0.61 | -0.66 |
| Average Basic Shares Outstanding | 81.59M | 81.21M | 80.77M | 80.29M | 79.76M |
| Average Diluted Shares Outstanding | 81.59M | 81.21M | 80.77M | 80.29M | 79.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |